Suzanne Tay

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development

James J. Crawford, Adam R. Johnson, Dinah Misner et al. · Journal of Medicinal Chemistry · 2018 · 240 citations · Full text

Tyrosine Kinase, Immunology, Biological Therapy +24

A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease–Drug Interactions: Suppression of CYP3A by IL-6

Krishna K. Machavaram, Lisa M. Almond, Amin Rostami‐Hodjegan et al. · Clinical Pharmacology & Therapeutics · 2013 · 107 citations

Cytokine Levels, Immunology, Physiologically-based Pharmacokinetic Modeling +20

Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases

Ariel R. Topletz, Jayne E. Thatcher, Alex Zelter et al. · Biochemical Pharmacology · 2011 · 107 citations · Full text

Aldehyde Dehydrogenase, Cellular Enzymology, Biochemistry +7

Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design

Matthew Volgraf, Benjamin D. Sellers, Yu Jiang et al. · Journal of Medicinal Chemistry · 2016 · 102 citations · Full text

Synaptic Transmission, Neurotransmitter, Synaptic Signaling +28

Drug–Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug–Drug Interaction Prediction

Jane R. Kenny, Sophie Mukadam, Chenghong Zhang et al. · Pharmaceutical Research · 2012 · 94 citations

Drug Interactions, Marketed Oncology Drugs, Preclinical Drug Evaluation +10